Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.49 |
| ▸ | HRH1 | P35367 | 7/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | HTR2B | P41595 | 5/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090143 | 0.89 | SLC6A2 (0.62) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL126823 | 0.89 | SLC6A2 (0.62) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| Hydrochloric Acid SCHEMBL14698993 | 0.87 | SLC6A2 (0.63) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL15908322 | 0.81 | CYP3A4 (0.50) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL21172138 | 0.80 | HTR2B (0.68) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL1695230 | 0.80 | HTR2B (0.68) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL1806812 | 0.79 | HRH1 (0.48) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL1803713 | 0.76 | SLC6A2 (0.49) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL17305922 | 0.76 | CHRM1 (0.45) | CHRM1HRH1SLC6A2LMNAHTR2B | |
| SCHEMBL11721982 | 0.74 | LMNA (0.61) | CHRM1HRH1SLC6A2LMNAHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | CHRM1 4822/4885HRH1 2583/4885SLC6A2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.